Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosedadult AML: A Retrospective Study of Chinese AML Patients

Chao-Ling Wan, Yuan-Hong Huang, Si-Man Huang, Tong-Tong Zhang, Kai-Wen Tan, Yan Qiu, Xiang-Dong Shen, Shuai-Shuai Ge, Han-Yu Cao, Yan-Yan Li, Songbai Liu, Qiao-Cheng Qiu, Haiping Dai, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 4216.

https://doi.org/10.1182/blood-2023-185390

Published: 2023

Journal Articles

Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China

Liqing Kang, Shengli Xue, Xiaowen Tang, Xiaoyan Lou, Chongsheng Qian, Wenjie Gong, Mingzhu Xu, Haixia Zhou, Zhen Yao, Wei Wang, Minghao Li, Nan Xu, Zhou Yu, Suning Chen, Huiying Qiu, Haiping Dai, Yang Xu, Depei Wu, Lei Yu

Blood (2023) 142 (Supplement 1): 3477.

https://doi.org/10.1182/blood-2023-181552

Published: 2023

Journal Articles

Venetoclax Combined with Hypomethylation Agents As Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia - Priliminary Results from a Real World Study in China

Haiping Dai, Jia Chen, Xiebing Bao, Depei Wu, Suning Chen

Blood (2023) 142 (Supplement 1): 1518.

https://doi.org/10.1182/blood-2023-189654

Published: 2023

Journal Articles

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

Blood (2023) 142 (Supplement 1): 889.

https://doi.org/10.1182/blood-2023-172615

Published: 2023

Journal Articles

Venetoclax, Cladribine and Cytarabine for the Treatment of Relapse/Refractory Acute Lymphoblastic Leukemia: Interim Analysis of a Phase 2 Trial

Yan-yan Li, Hai-xia Zhou, Si-man Huang, Chao-Ling Wan, Ming-zhu Xu, Wen-jie Gong, Chong-Sheng Qian, De-pei Wu, Haiping Dai, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2023-185312

Published: 2023

Journal Articles

Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML

Blood (2023) 142 (15): 1323–1327.

https://doi.org/10.1182/blood.2023020102

Published: 2023

Includes: Supplemental data

Journal Articles

Mutation Spectrum of FLT3 and Significance of Non-Canonical FLT3 Mutations in Hematological Malignancies

Shuai-Shuai Ge, Xiangdong Shen, Tianmei Wu, Jiahui Du, Haiping Dai, Qiaocheng Qiu, Songbai Liu, Depei Wu, Shengli Xue

Blood (2022) 140 (Supplement 1): 1425–1426.

https://doi.org/10.1182/blood-2022-159960

Published: 2022

Journal Articles

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1 -like Acute Lymphoblastic Leukemia

Haiping Dai, Wei Cui, Hongjie Shen, Qian Wang, Jia Yin, Zheng Li, Depei Wu, Xiaowen Tang

Blood (2022) 140 (Supplement 1): 10345–10346.

https://doi.org/10.1182/blood-2022-166687

Published: 2022

Journal Articles

Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia

Qian Wang, Haiping Dai, Wenzhi CAI, Qinrong Wang, Zhu Mingqing, Lingzhi Yan, Yan Yu, Hongjie Shen, Yang Xu, Ying Wang, Miao Miao, Shengli Xue, Yue Han, Xiaowen Tang, Huiying Qiu, Aining Sun, Jinyan Huang, Depei Wu, Suning Chen

Blood (2022) 140 (Supplement 1): 9198–9200.

https://doi.org/10.1182/blood-2022-156862

Published: 2022

Journal Articles

Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in Patients with Relapse/Refractory Acute Leukemia: Preliminary Results of a Phase II Study

Yanyan Li, Haixia Zhou, Chaoling Wan, Mingzhu Xu, Chongsheng Qian, Tongtong Zhang, Haiping Dai, AiNing Sun, Depei Wu, Shengli Xue

Blood (2022) 140 (Supplement 1): 3212–3213.

https://doi.org/10.1182/blood-2022-168054

Published: 2022

Journal Articles

Haplo-Identical Non-Gene Editing CD7 CAR T-Cells Induced Bone Marrow and Extramedullary Remission in a Pediatric Patient with TP53 Mutated Relapsed and Refractory Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma after Haploidentical Hematopoietic Stem Cell Transplantation

Haiping Dai, Yang Lin, Huimin Meng, Qingya Cui, Wenjuan Zhu, Xiaowen Tang, Wei Cui, Depei Wu

Blood (2021) 138 (Supplement 1): 4817.

https://doi.org/10.1182/blood-2021-151587

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR T-Cells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

Wei Cui, Xinyue Zhang, Haiping Dai, Qingya Cui, Jia Yin, Zheng Li, Lei Yu, Liqing Kang, Depei Wu, Xiaowen Tang

Blood (2021) 138 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2021-152565

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Blood (2021) 138 (Supplement 1): 1755.

https://doi.org/10.1182/blood-2021-152927

Published: 2021

Journal Articles

Decitabine in Combination with Fludarabine and Cyclophosphamide As Lymphodepletion Regimen Followed By CD19/CD22 Bispecific Targeted CAR-T Therapy Significantly Improves Survival in Relapsed/Refractory B-ALL Patients: A Pilot Study

Yunju Ma, Changju Qu, Haiping Dai, Sining Liu, Qingya Cui, Wei Cui, Jia Yin, Liqing Kang, Xiaying Lian, Huiying Qiu, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2021) 138 (Supplement 1): 1754.

https://doi.org/10.1182/blood-2021-152041

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study

Wei Cui, Xinyue Zhang, Haiping Dai, Qingya Cui, Baoquan Song, Depei Wu, MDPhD, Xiaowen Tang, MD PhD, Jia Yin, Zheng Li

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-143474

Published: 2020

Journal Articles

CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Xiaowen Tang, MD PhD, Depei Wu, MDPhD, Qingya Cui, Chongsheng Qian, Nan Xu, Liqing Kang, Haiping Dai, Baoquan Song, Wei Cui, Jia Yin, Zheng Li, Lei Yu, MD PhD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141602

Published: 2020

Journal Articles

Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations

Changju Qu, PhD, Jia Yin, Liqing Kang, Zheng Li, Haiping Dai, Xiaming Zhu, Lei Yu, Depei Wu, MD PhD, Xiaowen Tang

Blood (2019) 134 (Supplement_1): 3822.

https://doi.org/10.1182/blood-2019-128013

Published: 2019

Journal Articles

Decitabine As Part of a Modified Bu-Cy Conditioning Regimen Significantly Improved the Outcome of High-Risk AML Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Xiaowen Tang, Benigno C. Valdez, PhD, Qianqian Zhang, Yunju Ma, Haiping Dai, Jia Yin, Zheng Li, Ting Xu, Yang Xu, MD PhD, Jia Chen, Xiaming Zhu, Depei Wu, MD PhD, Borje S Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 3270.

https://doi.org/10.1182/blood-2019-123951

Published: 2019

Journal Articles

Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia

Yunju Ma, Changju Qu, PhD, Haiping Dai, Jia Yin, Zheng Li, Jia Chen, Huiying Qiu, Aining Sun, PhD, Miao Miao, Chengcheng Fu, Zhengming Jin, MD, Xiaming Zhu, Depei Wu, MD PhD, Xiaowen Tang

Blood (2019) 134 (Supplement_1): 3306.

https://doi.org/10.1182/blood-2019-124033

Published: 2019

Journal Articles

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Xiaowen Tang, Liqing Kang, Wei Qi, Wei Cui, Haiping Dai, Zheng Li, Jia Yin, Changju Qu, PhD, Ting Xu, Xiaming Zhu, Lei Yu, MD PhD, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 1338.

https://doi.org/10.1182/blood-2019-127890

Published: 2019

NARROW

RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosedadult AML: A Retrospective Study of Chinese AML Patients

Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China

Venetoclax Combined with Hypomethylation Agents As Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia - Priliminary Results from a Real World Study in China

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

Venetoclax, Cladribine and Cytarabine for the Treatment of Relapse/Refractory Acute Lymphoblastic Leukemia: Interim Analysis of a Phase 2 Trial

Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML

Mutation Spectrum of FLT3 and Significance of Non-Canonical FLT3 Mutations in Hematological Malignancies

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1 -like Acute Lymphoblastic Leukemia

Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia

Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in Patients with Relapse/Refractory Acute Leukemia: Preliminary Results of a Phase II Study

Haplo-Identical Non-Gene Editing CD7 CAR T-Cells Induced Bone Marrow and Extramedullary Remission in a Pediatric Patient with TP53 Mutated Relapsed and Refractory Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma after Haploidentical Hematopoietic Stem Cell Transplantation

Tandem CD19/CD22 Dual Targets CAR T-Cells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Decitabine in Combination with Fludarabine and Cyclophosphamide As Lymphodepletion Regimen Followed By CD19/CD22 Bispecific Targeted CAR-T Therapy Significantly Improves Survival in Relapsed/Refractory B-ALL Patients: A Pilot Study

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study

CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations

Decitabine As Part of a Modified Bu-Cy Conditioning Regimen Significantly Improved the Outcome of High-Risk AML Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only